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Objectives
To characterise bone scan use, and potential overuse, after
radical prostatectomy (RP) using data from a large, national
integrated delivery system. Overuse of imaging is well
documented in the setting of newly diagnosed prostate cancer,
but whether overuse persists after RP remains unknown.
Patients and methods
We identified 12 269 patients with prostate cancer treated
with RP between 2005 and 2008 using the Veterans
Administration Central Cancer Registry. We used
administrative and laboratory data to examine rates of bone
scan use, including preceding prostate-specific antigen (PSA)
levels, and receipt of adjuvant or salvage therapy. We then
performed multivariable logistic regression to identify factors
associated with post-RP bone scan use.
Results
At a median follow-up of 6.8 years, one in five men (22%)
underwent a post-RP bone scan at a median PSA level of
0.2 ng/mL. Half of bone scans (48%) were obtained in men
who did not receive further treatment with androgen-
deprivation or radiation therapy. After adjustment, post-RP
bone scan was associated with a prior bone scan (adjusted
odds ratio [aOR] 1.55, 95% confidence interval [CI] 1.32–
1.84), positive surgical margin (aOR 1.68, 95% CI 1.40–2.01),
preoperative PSA level (aOR 1.02, 95% CI 1.01–1.03), as well
as Hispanic ethnicity, Black race, and increasing D’Amico risk
category, but not with age or comorbidity.
Conclusion
We found a substantial rate of bone scan utilisation after
RP. The majority were performed for PSA levels of <1 ng/
mL where the likelihood of a positive test is low. More
judicious use of imaging appears warranted in the post-RP
setting.
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Introduction
Many men diagnosed with prostate cancer will undergo
diagnostic imaging at some point, either as part of initial
staging or to investigate rising PSA levels after treatment.
Guidelines recommend radionuclide bone scan use for
newly diagnosed men at high risk of metastasis or with
symptoms concerning for metastatic disease, and after
treatment in the setting of persistent or rising PSA
[1,2].
While bone scan use amongst the majority of newly
diagnosed men is unlikely to yield useful clinical information
(i.e., change treatment options), it remains common [3–10].
In fact, recent regional and national quality improvement
initiatives target bone scan overuse amongst newly diagnosed
men [11,12]. Whether similar initiatives are warranted to
promote high-value imaging use after radical prostatectomy
(RP) remains unknown. On the one hand, persistent (e.g.,
>0.2 ng/mL) or rising PSA levels after RP define biochemical
recurrence prompting imaging recommendations. On the
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other hand, although men with metastatic disease may
present with low PSA levels, most patients at these PSA levels
are asymptomatic and the likelihood of bone scans finding
metastatic disease amongst a cohort of post-RP men before
PSA levels exceed 10 ng/mL is well below 10%, except in
cases with extremely brisk PSA-doubling times [13–18].
While patients with local recurrence may be candidates for
salvage therapy, a PSA level threshold of 10 ng/mL remains
too high to inform clinical decision-making in many men
with recurrence but low PSA levels.
In this context, we examined bone scan use after RP in a
national integrated delivery system. We characterised
adjuvant and salvage therapy rates, investigated PSA levels at
the time of bone scan, and identified predictors associated
with post-RP bone scan use. A better understanding of bone
scan use after prostate cancer treatment will inform high-
value use of current imaging resources, and identify
considerations for emerging, expensive next-generation
imaging techniques [19,20].
Patients and methods
Study population
We used data from the Veterans Affairs Central Cancer
Registry (VACCR) to identify men with pathologically
confirmed incident diagnoses of prostate cancer between the
years 2005 and 2008, and available follow-up through 2013.
These records were linked with administrative files to obtain
clinical data. We excluded men with <2 years of follow-up, a
history of other malignancy, those enrolled in a hospice
within 30 days of diagnosis or who died within 6 months of
diagnosis, and those who were diagnosed at autopsy. Our
sample was then restricted to men who underwent RP as
their primary therapy per the VACCR, yielding a cohort of
12 269 patients.
Imaging use, biochemical recurrence, salvage and
adjuvant therapy
We identified receipt of imaging using the Healthcare
Common Procedure Coding System (HCPCS; codes 78300,
78305, 78315, 78320). We defined pre-treatment imaging use
as any bone scan ordered from the 6 months prior to
diagnosis until the date of RP. All bone scans ordered after
the date of RP were categorised as postoperative. We
considered the last PSA level obtained prior to the treatment
date from the laboratory data as the pre-treatment PSA level
[21]. We also assessed the post-treatment PSA nadir, as well
as the PSA level at the time of bone scan.
To better understand post-RP treatment patterns influencing
bone scan use, we defined biochemical recurrence as a PSA
level of ≥0.2 ng/mL in accordance with national guidelines
[1]. We used claims and pharmacy data to classify any
subsequent treatments as androgen-deprivation therapy
(ADT) or radiation therapy (XRT). Next, we characterised
XRT according to timing after RP to better understand
whether it was intended as adjuvant or salvage. We defined
adjuvant therapy as occurring at ≤1 year of RP, and salvage
therapy as occurring >1 year after RP. Lastly, we identified
PSA levels at the time of post-RP ADT or XRT use.
Statistical analysis
We used descriptive statistics to characterise our cohort
according to post-RP bone scan use. We examined a range of
demographic and clinical covariates, including age, race
(Black, White, Other), ethnicity (Hispanic, non-Hispanic,
unknown), marital status (married, divorced, single/never
married, widowed, unknown), VACCR Gleason score,
D’Amico risk group, surgical margin status (positive, negative,
unknown), and Charlson Comorbidity Index (CCI) score.
Next, we examined rates of, and time to, adjuvant and salvage
therapy, as well as the corresponding PSA levels at the time
of each therapy. Finally, we used multivariable logistic
regression to assess factors associated with receipt of bone
scan after RP. We selected variables a priori including: age,
race, ethnicity, marital status, D’Amico risk group, CCI score,
pretreatment PSA level, history of prior bone scan, and
surgical margin status.
All analyses were performed using the Statistical Analysis
System (SAS), version 9.4 (SAS Institute, Cary, NC, USA).
Statistical significance was evaluated using a significance level
of 0.05. This study was approved by the VA Ann Arbor
Healthcare System Institutional Review Board.
Results
Demographic characteristics of the 12 269 men treated with
RP are shown in Table 1. The mean age in this cohort was
62 years, and most men were diagnosed with low- or
intermediate-risk disease at a median PSA level of 5.6 ng/mL.
The median follow-up for the entire cohort was 81.4 months,
and all patients were followed for ≥5 years.
While one-third of the men in this cohort received a
preoperative bone scan (33%), one in five (22%) received at
least one bone scan (median 1, range 1–13) after RP, and
30% of men who received a bone scan underwent more
than one. As shown in Fig. 1, most patients undergoing a
post-RP bone scan had low- (22%) and intermediate-risk
(40%) prostate cancer. Moreover, the median PSA level at
the time of post-RP bone scan was 0.2 ng/mL, with 78% of
bone scans performed in men with PSA levels of <1 ng/mL.
While nearly half of patients (48%) undergoing a bone scan
received no subsequent treatment, men with low-risk disease
were less likely, and those with high-risk disease more likely,
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to have subsequent treatment with either ADT or XRT (P <
0.001).
As shown in Table 2, both adjuvant and salvage XRT were
more common in men who received bone scans (P < 0.001),
although time to XRT did not differ based on receipt of bone
scan. Men who received bone scans were also more likely to
receive ADT and do so later after RP. The receipt of bone
scan was associated with significantly higher PSA levels at
treatment for both salvage and adjuvant XRT, but not for
ADT. After multivariable adjustment, factors significantly
associated with bone scan were positive surgical margins,
preoperative PSA level, Hispanic ethnicity, Black race,
increasing D’Amico risk group, and history of a prior bone
scan (Table 3). After adjustment, we found no differences in
post-RP bone scan use according to patient comorbidity or
age. Rates of pre- and postoperative bone scan varied widely
across facilities, and did not appear to be correlated within
individual facilities (Fig. 2).
Discussion
One in five men in this large national integrated delivery
system underwent at least one postoperative bone scan
following RP. Nearly half of these scans were performed in
men who did not receive any additional treatment. The
median PSA level amongst men who received bone scans was
0.2 ng/mL, which suggests that half of the patients who
underwent a bone scan after RP did so before their PSA level
had reached the level of a biochemical recurrence. Even after
adjustment for patient and disease characteristics, receipt of
preoperative bone scan was a significant predictor of
postoperative imaging, which suggests that there may be non-
clinical variables (e.g., provider preference for ‘baseline’
studies) influencing the decision to pursue bone scan. The
wide range of usage across facilities further suggests an
opportunity for increased standardisation. Taken together,
these results suggest that there is opportunity for more
judicious use of postoperative bone scan, just as in the
pretreatment setting.
These findings suggest a higher rate of post-RP bone scan use
than found in prior studies and are reminiscent of imaging
overuse in the pretreatment setting [19]. While imaging
overuse in the evaluation of newly diagnosed prostate cancer
has been extensively studied, there is a paucity of literature
investigating post-treatment use. Interestingly, our present
findings are from an integrated delivery system that lacks
incentives for imaging, potentially underestimating bone scan
use in fee-for-service systems, and justifying post-treatment
efforts to decrease low value imaging. Our present results
regarding ethnicity are somewhat surprising given that studies
from other settings have found that minority populations
generally receive a lower intensity of follow-up, and we did
observe differences based on race/ethnicity with African-
American/Hispanic men more likely to undergo a bone scan
[22]. However, these findings may be reflective of more
aggressive disease in these men possibly incompletely
controlled for in our model [23].
For this population-based study, we were able to use PSA
levels prompting bone scan use amongst men treated with
RP. Unfortunately, our finding of low PSA levels at the time
of imaging indicates the results were unlikely to be clinically
useful. In other words, a negative imaging test at low PSA
levels is unable to differentiate local vs distant metastatic
disease and therefore adds little value to clinical decision-
making for men with biochemical recurrence as currently
defined. In fact, guidelines recommend consideration of bone
scan in the setting of biochemical recurrence; however,
indicate the likelihood of a positive result in the absence of
Table 1 Demographic characteristics of 12 269 men treated with RP for
incident diagnoses of prostate cancer stratified by receipt of
postoperative bone scan.
Demographics Bone
scan
No bone
scan
P
Number of patients 2652 9617
Age, years, mean (SD) 62.4 (8.0) 62.1 (7.2) 0.049
Race, %
Black 26 22 <0.001
White 71 75
Other/unknown 3 3
Ethnicity, %
Hispanic 7 4 <0.001
Non-Hispanic 92 95
Other/unknown 1 1
Marital status, %
Married 54 57 0.033
Divorced/separated 31 29
Single/never 8 8
Widowed 7 6
Other <1 <1
Employment status, %
Full-time 13 16 <0.001
Part-time 5 4
Retired 38 41
Self-employed 3 4
Unemployed 40 34
Active military <0.1 0
Unknown 1 1
CCI score, %
0 54 51 <0.01
1 25 24
2 21 25
PSA level at diagnosis,
ng/mL, median (range)
6.3
(0.1–96.4)
5.5
(0.1–97.2)
<0.001
Gleason Score, %
6 30 44 <0.001
7 47 47
8–10 23 9
D’Amico risk group, %
Low 22 35 <0.001
Intermediate 40 42
High 38 23
Positive surgical margins, % 31 19 <0.001
Follow-up, months, median (IQR) 83.3
(71.5–95.0)
80.9
(69.5–93.5)
<0.001
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symptoms and with PSA levels of <10 ng/mL is low [1]. For
example, one study found that men with PSA levels of
<10 ng/mL had positive bone scan rates ranging from 0% to
11%, depending on if PSA-doubling time was greater or less
than 6 months, and another estimated the probability of a
positive bone scan at <5% until PSA levels exceeded 40 ng/
mL [14,17]. However, this situation is made more
complicated by results suggesting that up to one in four men
with bone metastases after RP present with PSA levels of
<10 ng/mL [13]. Post-RP bone scan is likely warranted in
men with rapidly rising PSA levels or levels closer to 10 ng/
mL; however, that still excludes the many men in our present
cohort who received bone scans at far lower values.
Interestingly, studies suggest that implementation of salvage
XRT earlier in the postoperative period and at lower PSA
levels may confer benefits in the form of lower rates of
additional recurrence and metastasis [24]. In light of this,
eliminating bone scan altogether and proceeding directly to
salvage therapy for men with biochemical recurrence but low
PSA levels could be an approach to lower the use of
uninformative imaging while improving clinical outcomes.
Our present findings are also relevant to emerging diagnostic
techniques posited to improve post-treatment prostate cancer
surveillance, namely, positron emission tomography (PET)
imaging. Early findings suggest PET-based approaches may
improve staging of lymph nodes and distant metastases (e.g.,
bone) for men with newly diagnosed prostate cancer [25,26].
Relevant to our work, PET imaging is also increasingly used
to evaluate biochemical recurrence. The inability of current
600 
500 
400 
300 
200 
100 
0 
PSA 0.03 level ng/mL
PSA 0.5  level ng/mL
N
um
be
r o
f P
os
tp
er
at
iv
e B
on
e S
ca
ns
PSA 0.2 level ng/mL
PSA 0.5 level ng/mL
Low Risk Intermediate Risk High Risk 
No Treatment Adjuvant XRT Salvage XRT ADT 
Post-RP
Fig. 1 Distribution of postoperative bone scans across categories of adjuvant or salvage treatment and D’Amico risk group with median prostate-
specific antigen (PSA) levels at the time of bone scan. Most bone scans were obtained in men who did not receive postoperative therapy, and most
scans were in men with PSA levels <1 ng/mL.
Table 2 Treatment type and PSA levels amongst men who received additional therapy after RP stratified by receipt of postoperative bone scan.
Characteristic Bone scan No bone scan P
Number of patients 2652 9617
Any therapy, % 51.6 11.8 <0.001
XRT, % 14.3 3.6 <0.001
Adjuvant 3.5 1.1 <0.001
Salvage 10.8 2.5 <0.001
Time to XRT, months, median (IQR) 23.8 (12.5–46.4) 21.0 (10.6–43.0) 0.06
Adjuvant 8.1 (5.8–9.9) 7.7 (5.4–9.8) 0.6
Salvage 33.4 (20.2–52.7) 33.8 (18.9–49.6) 0.3
PSA level at XRT, ng/mL, median (range) 0.3 (0.0–0.9) 0.2 (0.0–3.7) <0.001
Adjuvant 0.5 (0.0–9.1) 0.1 (0.0–3.7) <0.001
Salvage 0.3 (0.0–9.4) 0.2 (0.0–3.3) <0.001
ADT, % 37.3% 8.2% <0.001
PSA level at ADT, ng/mL, median (range) 0.9 (0–2513) 0.2 (0–598) 0.1
Time to ADT, months, median (IQR) 12.2 (2.9–38.6) 8.3 (1.8–36.6) 0.05
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bone scan imaging techniques to adequately assess the source
of low but detectable PSA levels after surgery may be
frustrating for clinicians, spurring the promise and use of
PET imaging [27,28]. PET imaging utilising prostate-specific
membrane antigen (PSMA), in particular, appears to hold
promise in the evaluation of biochemical recurrence,
especially at lower PSA levels where the traditional bone scan
has been of limited use. Recent data from Gadzinski et al.
[29] suggest that nearly half of post-RP men with a PSA level
of 0.2 ng/mL may have detectable lesions using PSMA-PET,
with the detection rate improving to 100% amongst included
men with PSA levels of >6 ng/mL. Continuing work should
help to clarify the most effective ways to apply this new
technology and identify those men most likely to benefit.
Next-generation PET imaging could be harnessed to improve
the value of care by identifying patients with metastases who
would not benefit from local therapies such as salvage XRT.
However, the ability of advanced imaging techniques to
improve decision-making and clinical outcomes for these
patients remains to be fully explored.
While significant efforts are directed towards decreasing
imaging overuse in prostate cancer staging, we found similar
issues post-treatment that are not being addressed. From a
clinical perspective, a negative postoperative bone scan may
alleviate patient and clinician concerns about rising, although
low, PSA levels. It could also lead to salvage treatment with
XRT, as many scans in these data may have been ordered to
verify the absence of disseminated disease before localised
XRT. However, using negative bone scans as reassurance and
to differentiate local vs distant disease when it is unlikely to
yield accurate results could mislead patients and clinicians
resulting in misuse and overuse of treatment. These risks
must be weighed against the benefit of possible discovery of
some metastatic disease. In addition, we found that a
Table 3 Multivariable logistic regression results modelling the receipt of
bone scan after RP.
Covariate Adjusted odds ratio (95% CI)
Age 0.99 (0.98–1.01)
Race
White Referent
Black 1.32 (1.10–1.59)
Other 0.81 (0.51–1.30)
Ethnicity
Non-Hispanic Referent
Hispanic 1.58 (1.22–2.05)
Marital status
Married Referent
Divorced/separated 0.95 (0.79–1.13)
Never married 0.79 (0.58–1.07)
Widowed 0.97 (0.68–1.38)
D’Amico risk group
Low Referent
Intermediate 1.44 (1.16–1.77)
High 1.88 (1.49–2.36)
CCI score
0 Referent
1 0.85 (0.71–1.03)
2 1.12 (0.91–1.38)
Positive surgical margin 1.68 (1.40–2.01)
Preoperative PSA 1.02 (1.01–1.03)
Prior bone scan 1.55 (1.32–1.84)
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Fig. 2 Preoperative and postoperative bone scan rates across VHA facilities. The range of preoperative bone scan rates is large, with little apparent
correlation between the facility level use of preoperative and postoperative bone scan.
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previous bone scan was associated with post-RP bone scan
use, suggesting that some may be ordered based on non-
clinical factors such as provider perception or preference.
Lastly, consideration should be given to the natural history of
PSA progression after RP and to the life expectancy of
patients with biochemical recurrence years after their RP, as
we found age was not a factor in our adjusted analyses [30].
Better understanding competing risks for individual patients,
and how best to approach de-implementation of low-value
imaging in light of these risks appears warranted.
There are limitations to the present study. This study did
not include an assessment of PSA kinetics found to be at
least as important as PSA levels in predicting bone scan
positivity after biochemical recurrence. A subset of the
patients in the present study likely had rapid doubling times
prompting imaging despite low PSA levels. However, given
the median PSA level at bone scan of 0.2 ng/mL, our
overall conclusions regarding the extent to which imaging is
potentially low value is unchanged. The data used in the
present study lack information about the indication for
which imaging was obtained. It is possible that a number of
scans were obtained to evaluate common benign conditions,
such as persistent low back pain, to exclude malignancy as
an aetiological factor. It is unlikely that many men in the
present study would have had symptoms from metastasis-
related back pain due to the low PSA levels at the time of
bone scan. Additionally, prior studies examining bone scan
positivity after biochemical recurrence did not observe an
association between common symptoms, such as fatigue or
back pain, and bone scan results [15]. Next, whether recent
advances in the management of locally recurrent and
metastatic prostate cancer might have impacted imaging use
amongst prostate cancer survivors in our present study
remains unknown. However, use of advanced therapies
would theoretically only increase bone scan use to monitor
treatment effects. We also did not exclude men participating
in clinical trials. Lastly, we did not have results of the bone
scan studies. However, as many men were not treated after
the bone scan it was unlikely that these scans were positive
for disease. As ADT was the most commonly used salvage
treatment, it remained unclear whether this was used to
target biochemical recurrence, an increasingly scrutinised
practice [31], or metastatic disease to the bone, which would
be unusual for most PSA levels prompting bone scans in
the present study.
Despite these limitations, our present study has important
implications for current and future practice. While the AUA
has partnered with the American Board of Internal
Medicine’s Choosing Wisely campaign to help reduce the
routine use of bone scans in the staging of men with low-risk
prostate cancer, it appears that the potential for imaging
overuse in this population may persist in the postoperative
phase. As a point of comparison from another osteophilic
malignancy, historic data recommended obtaining serial post-
treatment bone scans in women after treatment for breast
cancer. Subsequent evidence has led to guidelines
recommending against the use of routine follow-up imaging
in otherwise asymptomatic women [32,33]. Focusing
increased attention on this aspect of prostate cancer
survivorship care will help decrease the burdens of
unnecessary testing and procedures. As imaging paradigms in
prostate cancer evolve, it will be critically important to
leverage these insights in guidelines and best practices. The
application of carefully considered testing thresholds will help
to minimise low-yield evaluations amongst prostate cancer
survivors, even as technology enables improved diagnostic
efficiency at lower PSA levels. De-implementation of
unnecessary imaging in the post-RP setting will spare
asymptomatic prostate cancer survivors inconvenience and
cost, likely without compromising quality and quantity of life.
We found relatively high rates of bone scan use following RP,
with many performed at PSA levels below the threshold for
biochemical recurrence. Our present results emphasise the
need to optimise post-RP imaging practices, much like those
amongst newly diagnosed men.
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